Illumina DRAGEN Bio-IT Platform: What’s new with version 3.6

Illumina Techsupport Webinar

Webinar Speakers

Shyamal Mehtalia
Principal Scientist,
Illumina Inc.

Shyamal Mehtalia is Principal Engineer at Illumina Inc. He is currently part of the Product Development group focusing on Customer Collaboration and Innovation with a focus on Secondary Analysis and Informatics development on the DRAGEN Bio-IT Platform. He drives key technical customer engagements for enabling Illumina’s secondary analysis solutions and provides support to Sales and Commercial organizations. He joined Illumina in May 2018 as part of the Edico Genome Corp. acquisition which invented the DRAGEN platform where he served as Director of Operations for 3 years. Previously he worked as a Manager at Broadcom Corp. in the Mobile Wireless Group and leading a team for 3G and 4G firmware development for Cellular Modems. Prior to that he held various R&D roles for System Design and Wireless signal processing for Cellular chipset development at Texas Instruments Inc.. Shyamal Mehtalia holds a Master degree in Electrical Engineering from Texas A&M University.
Webinar Abstract

The DRAGEN team is excited to announce the release of DRAGEN version 3.6. This version includes significant runtime improvements to the germline and somatic variant calling pipelines with the implementation of deBrujin graph construction on the DRAGEN FPGA. We are also excited to announce support for FASTQC statistics generation, poly-G trimming, and improvements to the JointGenotyping and CNV pipelines. This webinar is intended for all customers interested in hearing more about what’s new in DRAGEN. These features will be made available for on-site customers and also Cloud users on various platforms like BaseSpace and AWS Marketplace.

Register for the webinar
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see sapac.illumina.com/company/legal.html.

© 2025 Illumina, Inc. All rights reserved.